ArticleMolecular cell2023
Oncogenic K-Ras suppresses global miRNA function.
Open access · greenAbstract read
In one paragraph
Article in Molecular cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- Deciphering RNA and protein expression discordance identifies TOP2A as a prognostic biomarker and potential therapeutic target in lung adenocarcinoma.Discover oncology · 2026Article
- In vivo AGO-APP for cell-type- and compartment-specific miRNA profiling in the mouse brain.Cell reports methods · 2026Article
- Article
- Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development.Biomarker research · 2025Article
- Identification of Oncogene-Induced Senescence-Associated MicroRNAs.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Plant-based dietary miRNAS: cross-border regulatory factors for regulating glycolipid metabolism and their nutritional intervention strategies.Frontiers in nutrition · 2025Review
- [MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- In Silico Identification of Dysregulated miRNAs TargetingDiseases (Basel, Switzerland) · 2024Article
- Casein kinase 1 and 2 phosphorylate Argonaute proteins to regulate miRNA-mediated gene silencing.EMBO reports · 2023Article
- KRAS regulation of miRNA: Stepping on the brake to go faster.Molecular cell · 2023Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Bing ShuiDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02215, USA; Program in Biological and Biomedical Sciences, Division of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Tyler S BeyettDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Zhengyi ChenEpithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Cell and Developmental Biology, Chemical and Physical Biology Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Xiaoyi LiCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Gaspare La RoccaCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
William M GazlayDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Department of Chemistry, University of Massachusetts Boston, Boston, MA 02125, USA.
Michael J EckDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Ken S LauEpithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Cell and Developmental Biology, Chemical and Physical Biology Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Andrea VenturaCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kevin M HaigisDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02215, USA; Harvard Digestive Disease Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: kevin_haigis@dfci.harvard.edu.
Harvard University · USMemorial Sloan Kettering Cancer Center · USBrigham and Women's Hospital · USVanderbilt University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2019 to 2026
$19.6MSuper-Resolution ImagingP30NS072030 · NINDS · HARVARD MEDICAL SCHOOL · PI REGEHR, WADE G · 2011 to 2020
$5.8MTuft cell heterogeneity in function, lineage, and structure in ileal inflammatory diseaseR01DK103831 · NIDDK · VANDERBILT UNIVERSITY · PI LAU, KEN S · 2016 to 2024
$4.4MInvestigating the functions of the miR-17~92 family of oncogenic microRNA clustersR01CA149707 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VENTURA, ANDREA · 2010 to 2021
$3.8MTissue-specific genetic interactions in cancerR01CA232372 · NCI · DANA-FARBER CANCER INST · PI HAIGIS, KEVIN · 2018 to 2022
$2.9MInvestigating microRNA Function in Homeostasis, Regeneration and CancerR01CA245507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VENTURA, ANDREA · 2020 to 2024
$2.6MBasic and Translational studies of Ras-mutant colorectal cancerR01CA178017 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HAIGIS, KEVIN · 2014 to 2018
$1.8MStudies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancerF32CA247198 · NCI · DANA-FARBER CANCER INST · PI BEYETT, TYLER STEVEN · 2020 to 2022
$196kCancer Research UKNCI NIH HHS F32 CA247198NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA149707NCI NIH HHS R01 CA178017NCI NIH HHS R01 CA232372NCI NIH HHS R01 CA245507NIDDK NIH HHS R01 DK103831NINDS NIH HHS P30 NS072030
Abstract
K-Ras frequently acquires gain-of-function mutations (K-Ras
Indexed as
MicroRNAsNeoplasmsAnimalsCarcinogenesisCell Transformation, NeoplasticGenes, rasMiceProteomicsProto-Oncogene Proteins p21(ras)Hras protein, mouseMicroRNAsProto-Oncogene Proteins p21(ras)Ago2casein kinaseCLIP-seqcoloncolorectal cancerK-RasmiRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.